Management of 39-Week Pregnant Woman with Chickenpox Exposure
If this pregnant woman lacks evidence of immunity to varicella, administer VariZIG (varicella-zoster immune globulin) as soon as possible and within 10 days of exposure to prevent severe maternal complications, particularly varicella pneumonia. 1
Immediate Assessment Required
First, determine the patient's immunity status:
- Check varicella immunity history: Prior chickenpox infection, documented vaccination (2 doses), or positive VZV IgG antibody
- If immunity is uncertain or absent, proceed with prophylaxis immediately—do not delay for serology results if exposure was significant
Post-Exposure Prophylaxis Protocol
For Non-Immune Pregnant Women
VariZIG is the recommended prophylaxis for pregnant women without evidence of immunity 1. The CDC explicitly lists "pregnant women without evidence of immunity" as a priority group for VariZIG administration.
Dosing and timing:
- Administer 125 IU/10 kg body weight intramuscularly, up to maximum 625 IU (5 vials) 1
- Give as soon as possible after exposure, but within 10 days 1
- The 10-day window represents an extension from the previous 96-hour recommendation, based on evidence showing comparable disease attenuation when given up to 10 days post-exposure 1
Critical rationale: The primary indication for VariZIG in pregnancy is preventing severe maternal complications (particularly pneumonia, which causes significant morbidity and mortality), not preventing fetal infection or congenital varicella syndrome 2. At 39 weeks, the risk of congenital varicella syndrome is essentially zero, but maternal pneumonia risk remains substantial.
Alternative: Oral Acyclovir
Recent evidence suggests oral acyclovir may be equally effective as VariZIG for preventing maternal chickenpox (30.8% vs 36.6% infection rates, p=0.32) 3. However, since the CDC guidelines prioritize VariZIG and this is late-term pregnancy with high stakes, VariZIG remains the guideline-recommended first-line approach 1.
If VariZIG is unavailable or there are contraindications (history of anaphylaxis to human immune globulins, IgA deficiency with anti-IgA antibodies), consider oral acyclovir prophylaxis 3.
Post-Prophylaxis Monitoring
Observe for 28 days after exposure (not the typical 21-day incubation period) because VariZIG may prolong the incubation period by >1 week 1, 2.
If chickenpox develops despite prophylaxis:
- Institute immediate antiviral therapy (intravenous acyclovir for complicated disease) 2
- Monitor closely for varicella pneumonia—the leading cause of maternal mortality
Critical Peripartum Consideration
At 39 weeks gestation, there is a specific high-risk window for neonatal varicella:
If the mother develops chickenpox from 5 days before to 2 days after delivery, the neonate is at risk for severe, potentially fatal neonatal varicella (historically 17-30% severe disease rate, 31% mortality without modern intensive care) 2.
Neonatal management if maternal chickenpox occurs peripartum:
- Administer VariZIG to the newborn regardless of whether mother received it 2
- The neonate should receive VariZIG even if the mother was given prophylaxis, as maternal VariZIG does not prevent fetal infection 2
- Institute immediate antiviral therapy if the neonate develops any signs of varicella 1
Common Pitfalls to Avoid
- Don't wait for serology results if exposure was significant and immunity is uncertain—administer VariZIG empirically
- Don't assume VariZIG protects the fetus—it primarily protects the mother from complications 2
- Don't use the standard 21-day monitoring period—extend to 28 days due to prolonged incubation with VariZIG 1
- Don't forget neonatal prophylaxis if maternal chickenpox develops in the critical peripartum window (5 days before to 2 days after delivery) 1, 2
If Patient is Already Immune
No intervention needed. The patient and fetus are protected.